Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. [electronic resource]
Producer: 20171205Description: 50 p. digitalISSN:- 1756-8722
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Apoptosis -- drug effects
- Bridged Bicyclo Compounds, Heterocyclic -- therapeutic use
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Drug Synergism
- Female
- Gene Expression Profiling
- Heterografts
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Mice
- Myeloid Cell Leukemia Sequence 1 Protein
- Proto-Oncogene Proteins c-bcl-2 -- antagonists & inhibitors
- Proto-Oncogene Proteins c-mdm2 -- antagonists & inhibitors
- Pyrrolidines -- pharmacology
- Sequence Analysis, RNA
- Sulfonamides -- therapeutic use
- Tumor Suppressor Protein p53 -- genetics
- para-Aminobenzoates -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.